Contezolid
| Code | Size | Price |
|---|
| TAR-T28109-5mg | 5mg | £604.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28109-50mg | 50mg | £2,303.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28109-100mg | 100mg | £3,042.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
MRX-I, a monoamine oxidase-A (MAO-A) Inhibitor, is used potentially for the treatment of acute bacterial skin.
CAS:
1112968-42-9
Formula:
C18H15F3N4O4
Molecular Weight:
408.337
Purity:
0.98
SMILES:
Fc1cc(N2C[C@H](CNc3ccon3)OC2=O)c(F)c(F)c1N1CCC(=O)C=C1
References
1. Eckburg PB, Ge Y, Hafkin B. Single- and Multiple-Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects. Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02181-16. doi: 10.1128/AAC.02181-16. [Epub ahead of print] PubMed PMID: 28167545.
2. Meng J, Zhong D, Li L, Yuan Z, Yuan H, Xie C, Zhou J, Li C, Gordeev MF, Liu J, Chen X. Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-Dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos. 2015 May;43(5):646-59. doi: 10.1124/dmd.114.061747. PubMed PMID: 25710940.
3. Huang Y, Xu Y, Liu S, Wang H, Xu X, Guo Q, Wu B, Gordeev MF, Wang W, Yuan Z, Wang M. Selection and characterisation of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I. Int J Antimicrob Agents. 2014 May;43(5):418-22. doi: 10.1016/j.ijantimicag.2014.02.008. PubMed PMID: 24721233.
4. Li CR, Zhai QQ, Wang XK, Hu XX, Li GQ, Zhang WX, Pang J, Lu X, Yuan H, Gordeev MF, Chen LT, Yang XY, You XF. In vivo antibacterial activity of MRX-I, a new oxazolidinone. Antimicrob Agents Chemother. 2014;58(4):2418-21. doi: 10.1128/AAC.01526-13. PubMed PMID: 24395231; PubMed Central PMCID: PMC4023790.